CN113893214B - 喙尾琵甲提取物在化妆品中的应用 - Google Patents
喙尾琵甲提取物在化妆品中的应用 Download PDFInfo
- Publication number
- CN113893214B CN113893214B CN202111451516.4A CN202111451516A CN113893214B CN 113893214 B CN113893214 B CN 113893214B CN 202111451516 A CN202111451516 A CN 202111451516A CN 113893214 B CN113893214 B CN 113893214B
- Authority
- CN
- China
- Prior art keywords
- extract
- coracoid
- tail
- beak
- cosmetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 63
- 239000002537 cosmetic Substances 0.000 title claims abstract description 40
- 239000006286 aqueous extract Substances 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 230000002087 whitening effect Effects 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 24
- 238000002386 leaching Methods 0.000 claims description 20
- 210000003323 beak Anatomy 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- -1 7-acetyl-3, 6-dihydroxy-8-methyltetrahydronaphthalenone Chemical compound 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 3
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 claims 2
- OFSAJYZMIPNPHE-UHFFFAOYSA-N N-acetyldopamine Chemical compound CC(=O)NCCC1=CC=C(O)C(O)=C1 OFSAJYZMIPNPHE-UHFFFAOYSA-N 0.000 claims 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 claims 2
- IDSFKFXFMNGXCK-UHFFFAOYSA-N 1-(4-Methylphenyl)pyrrolidine-2,5-dione Chemical compound C1=CC(C)=CC=C1N1C(=O)CCC1=O IDSFKFXFMNGXCK-UHFFFAOYSA-N 0.000 claims 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 claims 1
- DZAUWHJDUNRCTF-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(O)C(O)=C1 DZAUWHJDUNRCTF-UHFFFAOYSA-N 0.000 claims 1
- VPRYSOJVBSTQKE-UHFFFAOYSA-N 5-ethylcyclohexane-1,3-dione Chemical compound CCC1CC(=O)CC(=O)C1 VPRYSOJVBSTQKE-UHFFFAOYSA-N 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 1
- WOOQSKAMMPIQIW-CIAFKFPVSA-N Bis(methylbenzylidene)sorbitol Chemical compound OC([C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=C(C)C=1C=CC=CC=1)=C(C)C1=CC=CC=C1 WOOQSKAMMPIQIW-CIAFKFPVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 229960003237 betaine Drugs 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 238000012827 research and development Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000401 methanolic extract Substances 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 241000238631 Hexapoda Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241001501039 Blaps Species 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 7
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000007760 free radical scavenging Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 241000254173 Coleoptera Species 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000219843 Pisum Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及中药化妆品技术领域,提供了喙尾琵甲水提取物在化妆品中的应用。本发明将喙尾琵甲水提物应用于化妆品中,开拓了喙尾琵甲在化妆品应用方面的价值,为功效性中药化妆品的研发和推广提供思路以及理论基础。实施例结果表明,喙尾琵甲水提取物安全性好,能够清除自由基、抑制黑色素产生、提高皮肤美白效果,具有抑菌活性,在制备美白化妆品方面具有广阔的应用前景。
Description
技术领域
本发明涉及中药化妆品技术领域,特别涉及喙尾琵甲水提取物在化妆品中的应用。
背景技术
喙尾琵甲,也称喙尾琵琶甲、云南琵琶甲、日本琵琶甲、日本琵琶甲云南亚种等,是云南彝族地区长期使用的一种药用昆虫,民间用于治疗肿瘤、心血管及类风湿等疑难病症的处方中,大多数都含有该昆虫成分。经前人不断验证,其含有多种有益成分,并且其营养物质丰富,含有9种人体必需微量元素、16种游离氨基酸和16种蛋白氨基酸,现代药理学研究表明其具有广泛的药理作用。
与化学合成成分相比,天然中药成分的优势表现为来源绿色、环保、可生物降解,安全性相对较高并具有一定的护肤效果。虽不及植物应用那么广泛,但昆虫作为中药应用在我国也有着几千年的历史,临床经验也证实昆虫作为中药应用,其具有护肤功效和使用安全性,我国古代长期积累的中药养颜、美容经验也为化妆品开发提供了线索和研发方向。
中国专利CN02134188.5公开了一种以云南琵琶甲提取物为作为主要成分的抗菌消炎制剂,该制剂中的琵甲提取物是以乙醇或其他醇作为溶剂进行提取的,且提取得到的琵甲提取物具有清热解毒、抗菌消炎的作用,可用于治疗急慢性支管炎、咽炎、牙周炎、牙龄炎及无名肿毒等症。目前,本领域中还没有将喙尾琵甲提取物应用于化妆品方面的报道。
发明内容
本发明目的在于提供一种喙尾琵甲水提取物在化妆品中的应用。本发明将喙尾琵甲水提取物应用于化妆品中,喙尾琵甲水提取物能够清除自由基、抑制黑色素产生、提高皮肤美白效果,在化妆品领域具有广阔的应用前景。
为了实现上述发明目的,本发明提供以下技术方案:
喙尾琵甲提取物在化妆品中的应用,所述喙尾琵甲提取物为喙尾琵甲水提物;
所述喙尾琵甲提取物的制备方法包括:
使用提取剂对喙尾琵甲粉末进行浸提,得到提取液;所述提取剂为水;
将所述提取液依次进行浓缩和冷冻干燥,得到喙尾琵甲提取物。
优选的,当所述提取剂为水时,所述浸提的温度为室温,次数为3~4次,每次浸提的时间为48~96h;所述浸提时喙尾琵甲粉末和水的体积比为1:3~5。
优选的,所述喙尾琵甲粉末由喙尾琵甲干虫粉碎过筛后得到。
优选的,所述过筛用筛网的目数为50目。
优选的,所述化妆品包括美白化妆品、抗氧化化妆品、抗菌化妆品或抗炎化妆品。
优选的,所述喙尾琵甲水提取物和补水保湿成分配合使用。
本发明提供了喙尾琵甲水提取物在化妆品中的应用,所述喙尾琵甲提取物为喙尾琵甲水提物;所述喙尾琵甲提取物的制备方法包括:使用提取剂对喙尾琵甲粉末进行浸提,得到提取液;所述提取剂为水;将所述提取液依次进行浓缩和冷冻干燥,得到喙尾琵甲提取物。本发明采用水对喙尾琵甲粉末提取,并对提取液进行浓缩和冻干,很大程度上消除了水的影响,然后将所得水提取物应用于化妆品中,开拓了喙尾琵甲在化妆品应用方面的价值,为功效性中药化妆品的研发和推广提供思路以及理论基础。实施例结果表明,喙尾琵甲水提取物安全性好,能够清除自由基、抑制黑色素产生、提高皮肤美白效果,具有抑菌活性,在制备美白化妆品方面具有广阔的应用前景。
附图说明
图1为实施例3中喙尾琵甲水提物细胞毒性检测结果;
图2为实施例3中喙尾琵甲醇提物细胞毒性检测结果;
图3为实施例4中喙尾琵甲水提物ABTS自由基清除活性检测结果;
图4为实施例4中喙尾琵甲醇提物ABTS自由基清除活性检测结果;
图5为实施例5中喙尾琵甲醇提物抑制IL-10炎症因子的检测结果;
图6为实施例5中喙尾琵甲醇提物抑制TNF-γ炎症因子的检测结果;
图7为实施例7中喙尾琵甲水提物酪氨酸酶抑制活性检测结果;
图8为实施例7中喙尾琵甲醇提物酪氨酸酶抑制活性检测结果。
具体实施方式
本发明提供了一种喙尾琵甲提取物在化妆品中的应用,所述喙尾琵甲提取物为喙尾琵甲水提物。
在本发明中,所述喙尾琵甲提取物的制备方法包括:
使用提取剂对喙尾琵甲粉末进行浸提,得到提取液;所述提取剂为水或乙醇;
将所述提取液依次进行浓缩和冷冻干燥,得到喙尾琵甲提取物;当所述提取剂为乙醇时,所得喙尾琵甲提取物为喙尾琵甲醇提物,当所述提取剂为水时,所得喙尾琵甲提取物为喙尾琵甲水提物。
本发明使用提取剂对喙尾琵甲粉末进行浸提,得到提取液;所述提取剂为水或乙醇。在本发明中,所述水优选为去离子水;当所述提取剂为水时,所述浸提的温度优选为室温,次数优选为3~4次,每次浸提的时间优选为48~96h,更优选为60~72h;所述浸提时喙尾琵甲粉末和水的体积比优选为1:3~5,更优选为1:4;本发明优选将每次浸提所得液体合并,得到提取液,当所述提取剂为水时,所得提取液为水提液。
在本发明中,当所述提取剂为乙醇时,所述乙醇的体积分数优选为70~95%,更优选为85~95%;所述浸提的温度优选为室温,次数优选为2~4次,更优选为3~4次,每次浸提的时间优选为48~96h,更优选为60~72h;所述浸提时喙尾琵甲粉末和乙醇的体积比优选为1:7~9,更优选为1:8;本发明优选将每次浸提所得液体合并,得到提取液,当所述提取剂为醇时,所得提取液为醇提液。
在本发明中,所述喙尾琵甲粉末由喙尾琵甲干虫粉碎过筛后得到,所述过筛用筛网的目数为50目,过筛后,取筛下物,即为所述喙尾琵甲粉末。本发明对所述喙尾琵甲干虫没有特殊要求,采用本领域技术人员熟知的喙尾琵甲干虫即可。
得到提取液后,本发明将所述提取液依次进行浓缩和冷冻干燥,得到喙尾琵甲醇提物。在本发明中,所述浓缩优选为减压浓缩,所述浓缩的温度优选为40~45℃,压力优选为0.06~0.1MPa,本发明通过浓缩去除提取液中的溶剂,消除溶剂对提取物功效的影响;在本发明中,浓缩所得浸膏的相对密度(以水为参考物质)优选为1.05~1.3;在本发明中,所述冷冻干燥优选在冻干机中进行;本发明对所述冷冻干燥的具体条件没有特殊要求,采用本领域技术人员熟知的条件即可。冷冻干燥后,所得冻干粉即为本发明的喙尾琵甲提取物;当所述提取剂为乙醇时,所得喙尾琵甲提取物为喙尾琵甲醇提物,当所述提取剂为水时,所得喙尾琵甲提取物为喙尾琵甲水提物。
在本发明中,所述化妆品优选包括美白化妆品、抗氧化化妆品、抗菌化妆品或抗炎化妆品;所述喙尾琵甲水提取物优选和补水保湿成分配合使用。本发明对所述喙尾琵甲水提取物在化妆品中的具体应用方法没有特殊要求,采用本领域技术人员熟知的方法,将喙尾琵甲水提取物添加到化妆品配方中,制备呈不同种类的化妆品即可,具体如乳液、膏霜等。
下面结合实施例对本发明提供的方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
将1kg喙尾琵甲干虫用粉碎机粉碎成粉末,过50目筛,并用90%的无水乙醇浸泡,喙尾琵甲粉末体积和无水乙醇的体积比为1:9,共浸提3次,每次浸泡72h,过滤后合并过滤液,在40~45℃,0.06~0.1MPa条件下减压浓缩至膏状,得到相对密度为1.05~1.30的喙尾琵甲醇提物浸膏,最后用冷冻冻干机冻干,即得喙尾琵甲醇提物冻干粉,将所得冻干粉应用于下列实施例中,进行功效测试。
对所得醇提物的成分进行鉴定,得出醇提物中包括的主要化学成分,具体如表1所示:
表1喙尾琵甲醇提物主要成分
实施例2
将1kg喙尾琵甲干虫用粉碎机粉碎成粉末,过50目筛,并用去离子水浸泡,喙尾琵甲粉末体积和水的体积比为1:4,共浸提3次,每次浸泡72h,过滤后合并过滤液,在40~45℃,0.06~0.1MPa条件下减压浓缩至膏状,得到喙尾琵甲水提物浸膏,最后用冷冻冻干机冻干,即得喙尾琵甲水提物冻干粉,将所得冻干粉应用于下列实施例中,进行功效测试。
对所得水提物的成分进行鉴定,得出水提物中包括的主要化学成分,具体如表2所示:
表2喙尾琵甲水提物主要成分
根据表2可以看出,喙尾琵甲水提物的主要成分均为对人体没有影响的有机物,且没有化妆品中不允许添加的物质,说明喙尾琵甲水提物应用于化妆品中,安全性较好。
实施例3:喙尾琵甲提取物安全性实验
喙尾琵甲水提物、醇提物对Raw264.7细胞毒性实验:
样品制备:将喙尾琵甲水提物用含10%胎牛血清、2%的青链霉素混合液的RPMI1640培养基配制成2mg/mL的初始溶液,将初始溶液进行2倍稀释,共得到浓度为2mg/mL、1mg/mL、0.5mg/mL、0.25mg/mL、0.125mg/mL、0.0625mg/mL、0.03175mg/mL、0.015875mg/mL的8个水提物样品;
将喙尾琵甲醇提物进行相同的配制和稀释,得到上述浓度的8个醇提物样品;
将上述8个浓度、共16个样品进行实验,具体步骤如下:
(1)铺板:将对数生长期的Raw264.7细胞用胰酶消化,加含10%胎牛血清、2%的青链霉素混合液的RPMI1640配制成细胞悬液,在96孔板中接种100μL的细胞悬液,每孔1×105个细胞,将96孔板置于37℃、5%CO2恒温培养箱培养;
(2)处理细胞:细胞贴壁后,将96孔板中的培养基吸出,加入100μL不同浓度的受试液,对照组不加入提取物溶液,加入相同剂量的PBS;将96孔板置于37℃、5%CO2恒温培养箱培养。
(3)24h后,向每孔加入10μL CCK-8溶液,注意不要打出气泡,以免影响读数。将96孔板置于37℃、5%CO2恒温培养箱培养1h左右,使用酶标仪测定其在450nm处的吸光度值,按照下式计算细胞的存活率。
细胞存活率=[(As-Ab)/(Ac-Ab)]×100%
其中:As:实验孔吸光度(含细胞、培养基、CCK-8溶液和药物溶液);
Ac:对照孔吸光度(含细胞、培养基、CCK-8溶液,不含药物);
Ab:空白孔吸光度(含培养基、CCK-8溶液,不含细胞、药物)。
所得结果如图1~2所示,图1为喙尾琵甲水提物细胞毒性检测结果,图2为喙尾琵甲醇提物细胞毒性检测结果。根据图1~2可以看出,同对照组(PBS)相比,水提物和醇提物在0.015875mg/mL~0.5mg/mL范围内,细胞存活率均明显增高,说明在此浓度范围内,喙尾琵甲水提取物在中药化妆品领域的应用是安全可靠的。
实施例4
喙尾琵甲水提物和喙尾琵甲醇提物对ABTS的清除作用
被测物质加入ABTS自由基溶液后,所含抗氧化成分能与ABTS自由基发生反应而使反应体系褪色,405nm的吸光度下降,在一定范围内其吸光度的变化与自由基被清除的程度成正比。采用ABTS自由基清除能力试剂盒通过测定吸光度下降的程度来反映喙尾琵甲提取物清除ABTS自由基的能力,步骤如下:
根据试剂盒操作步骤逐步操作,控制喙尾琵甲提取物的浓度分别为0.625mg/mL、1.25mg/mL、2.5mg/mL、5mg/mL、10mg/mL,充分混匀后室温避光静置6min,测定405nm处的吸光度;采用不加喙尾琵甲提取物的实验组为空白对照,采用不加ABTS的工作液作为对照组,采用维生素c作为阳性对照。空白管、对照管、标准管和测定管的吸光值分别记为A空白、A对照、A阳性对照和A测定。样本的自由基清除率计算公式如下:
ABTS自由基清除率D%=[A空白-(A测定-A对照)]÷A空白×100%
所得结果如图3~4所示,图3为喙尾琵甲水提物ABTS自由基清除活性检测结果,图4为喙尾琵甲醇提物ABTS自由基清除活性检测结果。根据图3可以看出,随着喙尾琵甲水提物浓度的增加,其对ABTS自由基清除率的活性增强,当喙尾琵甲水提物的浓度从0.625mg/mL增加到10mg/mL时,其清除率从39.83%增加到了91.3%。根据图4可以看出,当喙尾琵甲醇提物的浓度从0.625mg/mL增加到10mg/mL时,其清除率也从44.12%增加到了90.43%。以上结果表明,喙尾琵甲水提取物具有较强的抗氧化性。
实施例5
喙尾琵甲水提物和醇提物对经LPS刺激的Raw264.7巨噬细胞分泌TNF-γ、IL-10的影响,测试步骤如下:
(1)铺板:将对数生长期的Raw264.7细胞用胰酶消化,加含10%胎牛血清、2%的青链霉素混合液的RPMI1640配制成细胞悬液,在96孔板中接种100μL的细胞悬液,每孔1×106个细胞,将96孔板置于37℃、5%CO2恒温培养箱培养;
(2)LPS准备:将LPS用含2%的青链霉素混合液的RPMI1640培养基溶解,并稀释成2μg/mL的终浓度,将原先的细胞悬液吸出,改加每孔100μL的LPS,以不加LPS作为空白对照,培养24h;
(3)样品准备:取适量喙尾琵甲醇和水提物,加2%的青链霉素混合液的RPMI1640培养基溶解,将喙尾琵甲醇提物配制成2mg/mL的初始浓度,二倍稀释4个浓度的样品,并使用一次性注射器和0.22μm的过滤器对其进行过滤处理;
(4)处理细胞:LPS处理后,将96孔板中的培养基吸出,加入100μL不同浓度的受试液。将96孔板置于37℃、5%CO2恒温培养箱培养24h,以不加样品处理的LPS作为阴性对照,地塞米松作为阳性对照,培养24h。
(5)开始收集不同浓度的样品以及各对照组,用Elisa试剂盒检测不同样品对炎症因子的分泌量的效果。
结果发现,喙尾琵甲水提物没有消除炎症因子的作用,只有喙尾琵甲醇提物发挥了抗炎效果。图5~6为喙尾琵甲醇提物IL-10炎症因子和TNF-γ炎症因子的检测结果。根据图5~6可以看出,在LPS的刺激下,小鼠巨噬细胞的IL-10、TNF-γ这种促炎性因子的分泌量有所增加,经过不同浓度的喙尾琵甲醇提物处理后,与未经样品处理的LPS模型组相比,IL-10、TNF-γ的分泌量显著降低,说明喙尾琵甲醇提物对IL-10、TNF-γ具有明显的抑制作用。
实施例6
喙尾琵甲提取物对大肠杆菌和金黄色葡萄球菌的刺激作用
LB平板培养基接种:将灭菌的棉棒蘸取菌液,于管壁上挤去多余菌液,在LB平板培养基上均匀涂布,并沿平皿边缘环扫一圈,盖好平皿,干燥2min。将经过灭菌的直径为0.5cm的小滤纸片粘贴于培养基表面,分别取10μL水提物和醇提物(浓度为2mg/mL,溶剂为PBS)滴加于滤纸片中央,待滤纸片完全吸收样品之后,37℃恒温培养箱中倒置培养18~20h,观察是否有抑菌圈生成并做3次重复,测抑菌圈直径,将3组抑菌圈直径取平均值;抑菌圈实验判定标准:抑菌圈实验大于20mm,极敏;15~20mm,高敏;10~15mm,中敏;7~10mm,低敏;小于7mm,不敏感。
所得结果如表1所示:
表1喙尾琵甲提取物抑菌活性测试结果
表1中的结果表明,喙尾琵甲醇提物对大肠杆菌和金黄色葡萄球菌均具有一定程度的抑制作用,而水提物仅对金黄色葡萄球菌具有抑制作用。由于人体的皮肤暴露于空气中,其表面也会产生金黄色葡萄球菌、大肠杆菌等细菌类物质,在合适条件下,这些细菌会大量繁殖,对皮肤产生伤害,引发一些无法避免的炎症,因此,喙尾琵甲水提取物既对这些菌有效,也不会引发炎症,具有成为中药化妆品天然原料的应用潜力。
实施例7
喙尾琵甲提取物酪氨酸酶活性抑制实验,步骤如下:
将喙尾琵甲提取物(醇提物和水提物)溶解于PBS溶液中,配制成浓度为2mg/mL的初始溶液,然后将初始溶液进行二倍稀释,得到浓度为1mg/mL、0.5mg/mL、0.25mg/mL、0.125mg/mL、0.0625mg/mL的提取物溶液,作为待测样品。
取A、B、C、D四只试管,分别加入0.25mL的1mg/mL的L-酪氨酸溶液(溶剂为PBS),向A和C管中另加入0.25mL PBS溶液.向B和D管中分别加入0.25mL的待测样品。将4支试管中的溶液混匀,在37℃恒温水浴锅中加热10min后,于C和D管中加入0.25mL的0.07mg/mL的酪氨酸酶液,A和B管加入相同体积的PBS缓冲液补足测试样体积,在将四只试管置于37℃水浴锅继续保温反应20min。分别从4支试管中取上述试液加入石英比色皿中,用酶标仪检测475nm处的吸光值.按下式计算酪氨酸酶抑制率,以熊果苷作为阳性对照。
酪氨酸酶抑制率:I=[(C-A)-(D-B)]/(C-A)×100%
所得结果如图7~8所示,图7为喙尾琵甲水提物酪氨酸酶抑制活性检测结果,图8为喙尾琵甲醇提物酪氨酸酶抑制活性检测结果。根据图7~8可以看出,不同浓度的喙尾琵甲水提物与喙尾琵甲醇提物对照组相比,具有显著差异性(P<0.01),并且当浓度为1mg/mL时,喙尾琵甲水提物与喙尾琵甲醇提物的酪氨酸酶抑制率均能达到50%以上,以上结果表明,喙尾琵甲水提取物具有抑制黑色素的效果,具有美白作用。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (4)
1.喙尾琵甲提取物在制备美白化妆品中的应用,所述喙尾琵甲提取物为喙尾琵甲水提物;
所述喙尾琵甲提取物的制备方法包括:
使用提取剂对喙尾琵甲粉末进行浸提,得到提取液;所述提取剂为水;
将所述提取液依次进行浓缩和冷冻干燥,得到喙尾琵甲提取物;
所述浸提的次数为3~4次,每次浸提的时间为48~96h;所述浸提时喙尾琵甲粉末和水的体积比为1:3~5;所述浸提的温度为室温;
所述喙尾琵甲水提物的主要成分为:甜菜碱、3,4-二羟基苯基丙酸、N-乙酰多巴胺、5-乙基环己烷-1,3-二酮、4-甲氧基肉桂醛、7-乙酰基-3,6-二羟基-8-甲基四氢萘酮、苯甲酸丁酯、腺嘌呤、1-(4-甲基苯基)吡咯烷-2,5-二酮、 D-(+)-麦芽糖、双(甲基亚苄基)山梨糖醇、甘油磷酸甘油、癸烯酸、山梨酸。
2.根据权利要求1所述的应用,其特征在于,所述喙尾琵甲粉末由喙尾琵甲干虫粉碎过筛后得到。
3.根据权利要求2所述的应用,其特征在于,所述过筛用筛网的目数为50目。
4.根据权利要求1所述的应用,其特征在于,所述喙尾琵甲提取物和补水保湿成分配合使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111451516.4A CN113893214B (zh) | 2021-12-01 | 2021-12-01 | 喙尾琵甲提取物在化妆品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111451516.4A CN113893214B (zh) | 2021-12-01 | 2021-12-01 | 喙尾琵甲提取物在化妆品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113893214A CN113893214A (zh) | 2022-01-07 |
CN113893214B true CN113893214B (zh) | 2023-11-14 |
Family
ID=79195198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111451516.4A Active CN113893214B (zh) | 2021-12-01 | 2021-12-01 | 喙尾琵甲提取物在化妆品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113893214B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1415286A (zh) * | 2002-11-25 | 2003-05-07 | 谢金伦 | 一种以云南琵琶甲提取物作为主要成份的抗菌消炎制剂 |
CN101926828A (zh) * | 2010-02-08 | 2010-12-29 | 中国林业科学研究院资源昆虫研究所 | 提取琵琶甲中抑菌物质、水溶性多糖和甲壳素的方法 |
CN108498436A (zh) * | 2018-05-12 | 2018-09-07 | 大理大学 | 一种护肤抑菌洗手液及其制备方法 |
-
2021
- 2021-12-01 CN CN202111451516.4A patent/CN113893214B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1415286A (zh) * | 2002-11-25 | 2003-05-07 | 谢金伦 | 一种以云南琵琶甲提取物作为主要成份的抗菌消炎制剂 |
CN101926828A (zh) * | 2010-02-08 | 2010-12-29 | 中国林业科学研究院资源昆虫研究所 | 提取琵琶甲中抑菌物质、水溶性多糖和甲壳素的方法 |
CN108498436A (zh) * | 2018-05-12 | 2018-09-07 | 大理大学 | 一种护肤抑菌洗手液及其制备方法 |
Non-Patent Citations (4)
Title |
---|
国家药品监督管理局.《化妆品禁用原料目录》.2021,1、23. * |
国家食品药品监督管理总局.《化妆品安全技术规范》.2015,(第2015版版),前言、目录II、34. * |
施贵荣等.喙尾琵琶甲提取物体外抗菌作用初步研究.《时珍国医国药》.2011,第第22卷卷(第第22卷期),第622-623页. * |
裘炳毅等.《现代化妆品科学与技术:全3册》.中国轻工业出版社,2016,(第第1版版),8. * |
Also Published As
Publication number | Publication date |
---|---|
CN113893214A (zh) | 2022-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Evaluation of the antioxidant and hepatoprotective activity of Terminalia catappa | |
KR102026407B1 (ko) | 갈색거저리 발효 추출물을 유효성분으로 포함하는 항산화용 조성물 | |
Gautam et al. | Healing effects of Aegle marmelos (L.) Correa fruit extract on experimental colitis | |
CN107809998B (zh) | 柔毛肖乳香的水醇提取物、包含其的化妆品组合物及其美容用途 | |
KR20150086588A (ko) | 항염, 항알러지 및 항산화 효능이 우수한 Ge-8 혼합물을 함유하는 화장료 조성물 | |
JP5196416B2 (ja) | Limnocitruslittoralis抽出物を含有する化粧料組成物 | |
CN113893214B (zh) | 喙尾琵甲提取物在化妆品中的应用 | |
KR20070024147A (ko) | 리포좀으로 안정화 된 우렁쉥이 또는 멍게 외막 추출물을함유하는 피부 노화 억제 및 주름 개선 화장료 조성물 | |
CN113876614B (zh) | 一种甘草酸酐和金耳多糖降解产物复方组合物及其用途 | |
KR20200064384A (ko) | 약쑥을 함유한 항산화 및 항염증 화장료 조성물 | |
KR102477052B1 (ko) | 선복화 단백다당체 또는 선복화 올리고당/펩타이드 복합체를 유효성분으로 함유하는 피부 외용제 조성물 및 이의 제조방법 | |
JP3496967B2 (ja) | 抗プラスミン剤 | |
CN111979289B (zh) | 植提物抵抗皮肤化学性刺激的细胞学评价方法及其应用 | |
KR102421800B1 (ko) | 고염 미생물의 발효 추출물을 포함하는 조성물 | |
CN108420758A (zh) | 一种用生物酶加工和防腐的忍冬花植物提取液及其制备方法 | |
KR20150036882A (ko) | 곤드레 추출물을 포함하는 항산화 조성물 및 이의 제조방법 | |
KR20180124443A (ko) | 흰목이버섯 자실체 추출물을 포함하는 피부장벽강화용 화장료 조성물 | |
Nagadesi et al. | Taxonomy and Bioactive chemicals from Ganoderma and Phellinus of India | |
Ajayi et al. | Ulcer Healing Mechanism of Ethanolic Extract of Talinium triangulare in Male Wistar Rats | |
Johnson et al. | A study on antiurolithic and antioxidant activities of Glochidion velutinum leaves | |
US20190008756A1 (en) | Extract of dragon fruit flower, method for preparing the same, use thereof, and skin complexion improved composition thereof | |
TWI618540B (zh) | Composition for preventing renal toxicity caused by drug toxicity, preparation method thereof and Its use | |
CN106266582B (zh) | 短管兔耳草提取物其制备方法和应用、含其的皮肤外用剂 | |
JPH0597653A (ja) | 化粧品 | |
CN109771454A (zh) | 桦树茸提取物在制备治疗和/或预防高脂饮食致肝损伤相关疾病的制剂中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |